Get the Stockscreener App
6.099
0.07%
0.009
Rxsight Inc stock is traded at $6.099, with a volume of 23,719.
It is up +0.07% in the last 24 hours and up +16.08% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$6.09
Open:
$6.1
24h Volume:
23,719
Relative Volume:
0.02
Market Cap:
$253.30M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-6.3971
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
-11.55%
1M Performance:
+16.08%
6M Performance:
-29.39%
1Y Performance:
-30.19%
1-Day Range:
$6.08
$6.13
1-Week Range:
$5.945
$6.87
52-Week Range:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
6.09 | 256.21M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
114.59 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.78 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.17 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.67 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.47 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST - MarketBeat
Steven Cohen’s Point72 discloses RxSight (RXST) stake - Stock Titan
RxSight (RXST) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; Price Move - Vinanet
RxSight (RXST) Market: Moves 1.88% Higher to $6.49 in the Current Update; Boundary Watch: Support at $6.17 and Resistance at $6.81 Frame the Range on the DayATR Trailing Stop - Vinanet
Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight (RXST) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Price Reaction: The Stock Ends Down 1.70% in the Latest SessionGuidance Upgrade Report - Vinanet
RxSight (NASDAQ: RXST) ex-director to sell 11,890 shares - Stock Titan
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
RxSight (RXST) Close and Levels: Loses 2.31% to Close at $6.33 on the Day; Trading Range: Support at $6.01 and Resistance at $6.65 Frame the Range in the Available RecordAnchored VWAP - Vinanet
RxSight Inc. (RXST) Drops Nearly 6% as Shares Approach Key SupportMcClellan Summation - Vinanet
RxSight (RXST) Slips to $6.89 as Bearish Momentum Builds in Medical Device StockRVOL Spike - Vinanet
Walleye Capital LLC Takes Position in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery? - Yahoo Finance
RxSight (RXST) Q2 2026 Earnings Call Transcript - AOL.com
(RXST) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development - AOL.com
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alcon Q2 Sales Rise on Strength in Vision Care, Surgical Segments - VisionMonday.com
Eye care company Alcon raises margin outlook, shares jump - marketscreener.com
Stifel cuts RxSight stock price target on competitive headwinds By Investing.com - Investing.com India
RxSight Inc. (RXST) PT Lowered to $7 at Stifel Amid U.S. Adoption Challenges - StreetInsider
Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00 - MarketBeat
Stifel cuts RxSight stock price target on competitive headwinds - Investing.com
RxSight (RXST) offers to swap 4.08M underwater options for new awards - Stock Titan
Stifel Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $7 - Moomoo
RxSight Reports Q2 Financial Results, Provides Update on 2026 Outlook - VisionMonday.com
The RxSight, Inc. (NASDAQ:RXST) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Wall Street Zen Upgrades RxSight (NASDAQ:RXST) to Hold - MarketBeat
Levi & Korsinsky Notifies RxSight, Inc. (RXST) InvestorsLead Plaintiff Deadline on September 22, 2025 - The National Law Review
Rxsight Inc (RXST) Stock News Today - TradingKey
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $6 to $11 - moomoo.com
UBS Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $6.3 - Moomoo
UBS Group Boosts RxSight (NASDAQ:RXST) Price Target to $6.30 - MarketBeat
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 5 - GuruFocus
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside - Yahoo Finance
RxSight, Inc. Stock 12‑Month Price Target Cut to $7.91, Implies 26% Upside - TradingView
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $9 to $11 - moomoo.com
Rxsight, Inc. Reports Second Quarter 2026 Res - Moomoo
RxSight Q2 Earnings Call Highlights - MarketBeat
RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ... - finance.yahoo.com
RxSight (NASDAQ:RXST) Releases Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
RxSight, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
RXST: Q2 revenue was $33.7M, guidance withdrawn as business undergoes strategic reassessment - TradingView
Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance - Investing.com
Transcript : RxSight, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
RxSight Q2 adjusted loss beats estimates; withdraws 2026 guidance - TradingView
RxSight (RXST) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
RxSight, Inc. (RXST) Tops Q2 EPS by 25c - StreetInsider
RxSight, Inc. Q2 2026: Revenue $33.74M, EPS $(0.29) — 10-Q Summary - TradingView
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):